Barr Launches Generic Actiq

Law360, New York (September 28, 2006, 12:00 AM EDT) -- Barr Pharmaceuticals Inc. launched a generic version of Cephalon Inc.’s Actiq cancer pain reliever on Wednesday after an agreement with antitrust authorities gave Barr the license to make and sell the generic version to alleviate competition concerns.

When Cephalon acquired Cima Labs for $515 million, the FTC allowed the merger to proceed on the condition that Barr be allowed to compete by producing the same drug.

The Federal Trade Commission approved the agreement in August 2004, but several elements held up the launch.

Barr’s license for...
To view the full article, register now.